Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Netherlands

Netherlands

The Netherlands is projected to experience significant growth in the Neoplasm Treatment market.
By 2024, revenue in this market is expected to reach US$2.68bn.
Furthermore, it is estimated that the market will continue to expand at a compound annual growth rate (CAGR) of 3.87% from 2024 to 2029, resulting in a market volume of US$3.24bn by 2029.
When compared to other countries globally, United States is anticipated to generate the highest revenue in the Neoplasm Treatment market.
In 2024, United States is expected to generate a staggering US$90.56bn.
The Netherlands has a strong focus on research and innovation in neoplasm treatment, with a particular emphasis on personalized medicine.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.